Risk predictors for adverse COVID-19 outcomes in Latin American patients with autoimmune rheumatic diseases: A multicentre study in Ecuador and Mexico

Q3 Health Professions

Revista Colombiana de Reumatologia Pub Date : 2025-04-01 DOI:10.1016/j.rcreu.2024.02.004

Santiago Guzmán-García , Goethe Sacoto-Flores , Johanna Román-Bermeo , Fabiana Samaniego-Burneo , María Ochoa , Franklin Uguña-Sari , Gladis Molina-Alvarado , Luis M. Amezcua-Guerra

{"title":"Risk predictors for adverse COVID-19 outcomes in Latin American patients with autoimmune rheumatic diseases: A multicentre study in Ecuador and Mexico","authors":"Santiago Guzmán-García , Goethe Sacoto-Flores , Johanna Román-Bermeo , Fabiana Samaniego-Burneo , María Ochoa , Franklin Uguña-Sari , Gladis Molina-Alvarado , Luis M. Amezcua-Guerra","doi":"10.1016/j.rcreu.2024.02.004","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction/objectives</h3><div>The understanding of COVID-19 progression among patients with autoimmune rheumatic diseases (SARDs) in Latin America remains limited. This study aimed to identify risk predictors associated with poor outcomes of COVID-19 in patients with SARDs.</div></div><div><h3>Materials and methods</h3><div>An observational multicentre study including patients with SARDs from Ecuador and Mexico.</div></div><div><h3>Results</h3><div>A total of 103 patients (78% women), aged 52.5±17.7 years, were enrolled. The most prevalent SARDs were rheumatoid arthritis (59%) and systemic lupus erythematosus (SLE; 24%). Severe COVID-19 was observed in 28% of patients at admission, 43% experienced complications during follow-up, and 8% ultimately died. Mortality rates were highest in patients with antiphospholipid syndrome (27%) or SLE (20%). Poor prognostic factors included acute respiratory distress syndrome (odds ratio [OR]=17.07), severe COVID-19 at admission (OR=11.45), and presence of SLE (OR=4.62). In multivariate analysis, SLE emerged as the sole predictor of mortality (OR=15.61).</div></div><div><h3>Conclusions</h3><div>Patients with SARDs in Latin America face significant risks of adverse COVID-19 outcomes, with SLE being a major risk factor for mortality.</div></div>","PeriodicalId":37643,"journal":{"name":"Revista Colombiana de Reumatologia","volume":"32 2","pages":"Pages 152-158"},"PeriodicalIF":0.0000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Revista Colombiana de Reumatologia","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0121812324000343","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Health Professions","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction/objectives

The understanding of COVID-19 progression among patients with autoimmune rheumatic diseases (SARDs) in Latin America remains limited. This study aimed to identify risk predictors associated with poor outcomes of COVID-19 in patients with SARDs.

Materials and methods

An observational multicentre study including patients with SARDs from Ecuador and Mexico.

Results

A total of 103 patients (78% women), aged 52.5 ± 17.7 years, were enrolled. The most prevalent SARDs were rheumatoid arthritis (59%) and systemic lupus erythematosus (SLE; 24%). Severe COVID-19 was observed in 28% of patients at admission, 43% experienced complications during follow-up, and 8% ultimately died. Mortality rates were highest in patients with antiphospholipid syndrome (27%) or SLE (20%). Poor prognostic factors included acute respiratory distress syndrome (odds ratio [OR] = 17.07), severe COVID-19 at admission (OR = 11.45), and presence of SLE (OR = 4.62). In multivariate analysis, SLE emerged as the sole predictor of mortality (OR = 15.61).

Conclusions

Patients with SARDs in Latin America face significant risks of adverse COVID-19 outcomes, with SLE being a major risk factor for mortality.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Revista Colombiana de Reumatologia Medicine-Rheumatology

CiteScore

0.80

自引率

0.00%

发文量

期刊介绍： The Colombian Journal of Rheumatology (Revista Colombiana de Reumatología) is the official organ of the Colombian Association of Rheumatology (Asociación Colombiana de Reumatología) and the Central American, Caribbean and Andean Association of Rheumatology (Asociación Centroamericana Caribe Andina de Reumatología) - ACCA. It was created in December 1993 with the purpose of disseminating scientific information derived from primary and secondary research and presenting cases coming from the practice of Rheumatology in Latin America. Since its foundation, the Journal has been characterized by its plurality with subjects of all rheumatic and osteomuscular pathologies, in the form of original articles, historical articles, economic evaluations, and articles of reflection and education in Medicine. It covers an extensive area of topics ranging from the broad spectrum of the clinical aspects of rheumatology and related areas in autoimmunity (both in pediatric and adult pathologies), to aspects of basic sciences. It is an academic tool for the different members of the academic and scientific community at their different levels of training, from undergraduate to post-doctoral degrees, managing to integrate all actors inter and trans disciplinarily. It is intended for rheumatologists, general internists, specialists in related areas, and general practitioners in the country and abroad. It has become an important space in the work of all rheumatologists from Central and South America.